ZyVersa Therapeutics, Inc. Annual Report: A Simple Breakdown

I’ve put together this guide to help you understand how ZyVersa Therapeutics performed this year. My goal is to translate complex financial filings into plain English so you can decide if this company fits your investment goals.

1. What does this company do?

ZyVersa is a clinical-stage biotech company. Think of them as a laboratory-focused startup rather than a traditional business. They do not sell products yet. Instead, they are developing two drug platforms licensed from the University of Miami:

• VAR 200: An injectable drug designed to remove excess cholesterol from the kidneys. It aims to treat rare, chronic kidney diseases like FSGS and Alport syndrome.
• IC 100: An antibody treatment that targets the body’s "internal alarm system" for inflammation. This could help treat conditions like NASH, diabetic kidney disease, and multiple sclerosis.

2. Financial performance: Still in "Burn Mode"

ZyVersa is currently in "burn mode." For the year ending December 31, 2023, the company reported $0 in revenue. They lost approximately $13.4 million, mostly due to $7.5 million in research costs and $5.9 million in administrative expenses.

Because they have no products on the market, they cover these costs by selling more shares of the company. As of their latest report, they had about $3.2 million in cash. They must frequently raise more money by issuing stock and warrants to keep the lights on.

3. Major wins and upcoming milestones

The company has an ambitious roadmap for the next 18 months:

• Kidney Pipeline (VAR 200): After finishing a Phase 2a clinical trial, the company is preparing for regulatory discussions. They plan to start the next stage of clinical development by the second quarter of 2026.
• Inflammation Pipeline (IC 100): They are running studies to support an application to the FDA. They aim to submit this in late 2026 and start Phase 1 trials shortly after.
• Strategy: They use a "platform" approach to target multiple diseases. This strategy aims to make their drugs more attractive for future partnerships or buyouts by larger pharmaceutical companies.

4. Financial health and risks

This is a very small company, and the risks are high:

• Dilution: Because they have no revenue, they frequently issue new shares to raise cash. This creates more shares, which reduces your ownership percentage in the company.
• Going Concern Risk: Auditors have flagged a "going concern" warning. This means there is significant doubt about the company’s ability to stay in business over the next 12 months without raising more money.
• Market Status: The stock trades on the OTCQB market. This market has less oversight than the major exchanges, which can lead to higher price swings and difficulty buying or selling shares at your target price.

5. The Bottom Line

ZyVersa is a high-risk, high-reward bet on scientific research. They are not a profitable business; they are a research project with a limited cash supply. If their trials succeed, the company could become very valuable through a partnership or sale. If the trials fail, or if they run out of cash, the investment could lose its entire value.

Investor Tip: Before investing, ask yourself if you are comfortable with the high volatility typical of "going concern" biotech stocks. If you decide to move forward, consider keeping your position size small, as the company relies entirely on future clinical success and ongoing fundraising to survive.